# Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets

## TL;DR

This review explores how long non-coding RNAs contribute to neuroblastoma and their potential as biomarkers and therapeutic targets.

## Contribution

The paper provides an updated review of the role of long non-coding RNAs in neuroblastoma pathogenesis and clinical applications.

## Key findings

- Long non-coding RNAs are involved in neuroblastoma onset, progression, and treatment resistance.
- These RNAs show promise as diagnostic, prognostic, and therapeutic tools in neuroblastoma.
- Recent omics studies highlight the clinical relevance of long non-coding RNAs in childhood cancer.

## Abstract

Neuroblastoma is the most common malignant extracranial solid tumor of childhood. Recent studies involving the application of advanced high-throughput “omics” techniques have revealed numerous genomic alterations, including aberrant coding-gene transcript levels and dysfunctional pathways, that drive the onset, growth, progression, and treatment resistance of neuroblastoma. Research conducted in the past decade has shown that long non-coding RNAs, once thought to be transcriptomic noise, play key roles in cancer development. With the recent and continuing increase in the amount of evidence for the underlying roles of long non-coding RNAs in neuroblastoma, the potential clinical implications of these RNAs cannot be ignored. In this review, we discuss their biological mechanisms of action in the context of the central driving mechanisms of neuroblastoma, focusing on potential contributions to the diagnosis, prognosis, and treatment of this disease. We also aim to provide a clear, integrated picture of future research opportunities.